Skip to main content

Avelumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 16, 2023.

Applies to avelumab: intravenous solution.

Serious side effects of Avelumab

Along with its needed effects, avelumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking avelumab:

More common

Less common


Other side effects of Avelumab

Some side effects of avelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to avelumab: intravenous solution.


Very common (10% or more): Hypotension (25%), hypertension (13%)

Uncommon (0.1% to 1%): Myocarditis[Ref]


Very common (10% or more): Urticaria (25%), rash (e.g., maculopapular, erythema, dermatitis bullous) (22%), pruritus (10%)

Uncommon (0.1% to 1%): Psoriasis, arthritis, exfoliative dermatitis, pemphigoid, Stevens Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), histiocytic necrotizing lymphadenitis, vasculitis, hypophysitis[Ref]


Common (1% to 10%): Immune-mediated thyroid disorders (hypothyroidism/hyperthyroidism)

Uncommon (0.1% to 1%): Adrenal insufficiency, hypopituitarism, hypophysitis[Ref]


Very common (10% or more): Abdominal pain (25%), diarrhea (23%), nausea (22%), constipation (17%)

Common (1% to 10%): Immune-mediated colitis

Uncommon (0.1% to 1%): Pancreatitis[Ref]


Very common (10% or more): Lymphopenia (49%), anemia (35%), thrombocytopenia (27%)

Common (1% to 10%): Neutropenia

Rare (0.01% to 0.1%): Hemolytic anemia[Ref]


Very common (10% or more): Increased aspartate aminotransferase (AST) (34%), increased alanine aminotransferase (ALT) (20%)

Common (1% to 10%): Increased bilirubin

Uncommon (0.1% to 1%): Immune-mediated hepatitis[Ref]


Common (1% to 10%): Immunogenicity[Ref]


Very common (10% or more): Anorexia (20%), weight loss (15%), increased lipase (14%)

Common (1% to 10%): Increased amylase[Ref]


Very common (10% or more): Anorexia (20%), weight loss (15%), increased lipase (14%)

Common (1% to 10%): Increased amylase[Ref]


Very common (10% or more): Musculoskeletal pain (32%), back pain (25%), arthralgia (16%)

Common (1% to 10%):

Uncommon (0.1% to 1%): Myositis, rhabdomyolysis, myasthenia gravis[Ref]

Nervous system

Very common (10% or more): Dizziness (14%), headache (10%)

Uncommon (0.1% to 1%): Guillain-Barre syndrome, demyelination, encephalitis[Ref]


Very common (10% or more): Couth (18%), dyspnea (11%)

Common (1% to 10%): Immune-mediated pneumonitis, wheezing[Ref]


Rare (less than 0.1%): Immune-mediated nephritis[Ref]


Very common (10% or more): Fatigue (50%), pyrexia (25%), chills (25%), flushing (25%), peripheral edema (20%)[Ref]


Uncommon (0.1% to 1%): Uveitis, iritis[Ref]

Frequently asked questions


1. (2017) "Product Information. Bavencio (avelumab)." EMD Serono Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.